Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin

mAbs

Volumn 6, Issue 2, 2014, Pages 354-366

  Kornberger, Petra ^a   Skerra, Arne ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antibody drug conjugate; Binding protein; Immunotoxin; Plant toxin; Protein ligation; Transpeptidation

Indexed keywords

BACTERIAL ENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELONIN; IMMUNOGLOBULIN F(AB) FRAGMENT; SORTASE A; TRASTUZUMAB; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; LARYNX CANCER; SURFACE PLASMON RESONANCE;

ANTIBODY-DRUG CONJUGATE; BINDING PROTEIN; IMMUNOTOXIN; PLANT TOXIN; PROTEIN LIGATION; TRANSPEPTIDATION;

ADENOCARCINOMA; AMINOACYLTRANSFERASES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BACTERIAL PROTEINS; BREAST NEOPLASMS; CATALYSIS; CELL LINE, TUMOR; CHROMATOGRAPHY, AFFINITY; CYSTEINE ENDOPEPTIDASES; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOTHERAPY, ACTIVE; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; RIBOSOME INACTIVATING PROTEINS, TYPE 1;

EID: 84896524075     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.27444     Document Type: Article

References (89)

1. Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012; 4:413-5; PMID:22531442; http://dx.doi.org/10.4161/mabs.19931
2. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J 2008; 14:154-69; PMID:18536555; http://dx.doi.org/10.1097/PPO. 0b013e318172d704
3. Ricart AD. Immunoconjugates against solid tumors: mind the gap. Clin Pharmacol Ther 2011; 89:513-23; PMID:21368753; http://dx.doi.org/10.1038/clpt. 2011.8
4. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23:1126-36; PMID:16151406; http://dx.doi.org/10.1038/nbt1142
5. Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 2009; 13:245-55; PMID:19501012; http://dx.doi.org/10.1016/j.cbpa.2009.04.627
6. Mazmanian SK, Liu G, Ton-That H, Schneewind O. Staphylococcus aureus sortase, an enzyme that anchors surface proteins to the cell wall. Science 1999; 285:760-3; PMID:10427003; http://dx.doi.org/10.1126/science.285.5428.760
7. Mazmanian SK, Ton-That H, Schneewind O. Sortase-catalysed anchoring of surface proteins to the cell wall of Staphylococcus aureus. Mol Microbiol 2001; 40:1049-57; PMID:11401711; http://dx.doi.org/10.1046/j.1365-2958.2001.02411.x
8. Hendrickx AP, Budzik JM, Oh SY, Schneewind O. Architects at the bacterial surface - sortases and the assembly of pili with isopeptide bonds. Nat Rev Microbiol 2011; 9:166-76; PMID:21326273; http://dx.doi.org/10.1038/nrmicro2520
9. Marraffini LA, Dedent AC, Schneewind O. Sortases and the art of anchoring proteins to the envelopes of Gram-positive bacteria. Microbiol Mol Biol Rev 2006; 70:192-221; PMID:16524923; http://dx.doi.org/10.1128/MMBR.70.1.192-221. 2006
10. Ton-That H, Liu G, Mazmanian SK, Faull KF, Schneewind O. Purification and characterization of sortase, the transpeptidase that cleaves surface proteins of Staphylococcus aureus at the LPXTG motif. Proc Natl Acad Sci U S A 1999; 96:12424-9; PMID:10535938; http://dx.doi.org/10.1073/pnas.96.22.12424
11. Madej MP, Coia G, Williams CC, Caine JM, Pearce LA, Attwood R, Bartone NA, Dolezal O, Nisbet RM, Nuttall SD, et al. Engineering of an anti-epidermal growth factor receptor antibody to single chain format and labeling by Sortase A-mediated protein ligation. Biotechnol Bioeng 2012; 109:1461-70; PMID:22170409; http://dx.doi.org/10.1002/bit.24407
12. Möhlmann S, Mahlert C, Greven S, Scholz P, Harrenga A. In vitro sortagging of an antibody Fab fragment: overcoming unproductive reactions of sortase with water and lysine side chains. ChemBioChem 2011; 12:1774-80; PMID:21656631; http://dx.doi.org/10.1002/cbic.201100002
13. Parthasarathy R, Subramanian S, Boder ET. Sortase A as a novel molecular "stapler" for sequence-specific protein conjugation. Bioconjug Chem 2007; 18:469-76; PMID:17302384; http://dx.doi.org/10.1021/bc060339w
14. Antos JM, Miller GM, Grotenbreg GM, Ploegh HL. Lipid modification of proteins through sortase-catalyzed transpeptidation. J Am Chem Soc 2008; 130:16338-43; PMID:18989959; http://dx.doi.org/10.1021/ja806779e
15. Samantaray S, Marathe U, Dasgupta S, Nandicoori VK, Roy RP. Peptide-sugar ligation catalyzed by transpeptidase sortase: a facile approach to neoglycoconjugate synthesis. J Am Chem Soc 2008; 130:2132-3; PMID:18229923; http://dx.doi.org/10.1021/ja077358g
16. Tanaka T, Yamamoto T, Tsukiji S, Nagamune T. Site-specific protein modification on living cells catalyzed by Sortase. ChemBioChem 2008; 9:802-7; PMID:18297670; http://dx.doi.org/10.1002/cbic.200700614
17. Levary DA, Parthasarathy R, Boder ET, Ackerman ME. Protein-protein fusion catalyzed by sortase A. PLoS One 2011; 6:e18342; PMID:21494692; http://dx.doi.org/10.1371/journal.pone.0018342
18. Stirpe F, Olsnes S, Pihl A. Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A. J Biol Chem 1980; 255:6947-53; PMID:7391060
19. Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies. Cancer Res 2009; 69:8987-95; PMID:19934334; http://dx.doi.org/10.1158/0008-5472.CAN-09-2693
20. 121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. Neoplasia 2005; 7:912-20; PMID:16242074; http://dx.doi.org/10. 1593/neo.05292
21. rd. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. Cancer Res 2003; 63:3995-4002; PMID:12873997
22. Lyu MA, Cao YJ, Mohamedali KA, Rosenblum MG. Cell-targeting fusion constructs containing recombinant gelonin. Methods Enzymol 2012; 502:167-214; PMID:22208986; http://dx.doi.org/10.1016/B978-0-12-416039-2.00008-2
23. Urbatsch IL, Sterz RK, Peper K, Trommer WE. Antigen-specific therapy of experimental myasthenia gravis with acetylcholine receptor-gelonin conjugates in vivo. Eur J Immunol 1993; 23:776-9; PMID:8449224; http://dx.doi.org/10.1002/ eji.1830230332
24. Hossann M, Li Z, Shi Y, Kreilinger U, Büttner J, Vogel PD, Yuan J, Wise JG, Trommer WE. Novel immunotoxin: a fusion protein consisting of gelonin and an acetylcholine receptor fragment as a potential immunotherapeutic agent for the treatment of Myasthenia gravis. Protein Expr Purif 2006; 46:73-84; PMID:16230023; http://dx.doi.org/10.1016/j.pep.2005.08.029
25. Borthakur G, Rosenblum MG, Talpaz M, Daver N, Ravandi F, Faderl S, Freireich EJ, Kadia T, Garcia-Manero G, Kantarjian H, et al. Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica 2013; 98:217-21; PMID:22875630; http://dx.doi.org/ 10.3324/haematol.2012.071092
26. Daubenfeld T, Hossann M, Trommer WE, Niedner-Schatteburg G. On the contentious sequence and glycosylation motif of the ribosome inactivating plant protein gelonin. Biochem Biophys Res Commun 2005; 333:984-9; PMID:15967415; http://dx.doi.org/10.1016/j.bbrc.2005.06.008
27. Nolan PA, Garrison DA, Better M. Cloning and expression of a gene encoding gelonin, a ribosome-inactivating protein from Gelonium multiflorum. Gene 1993; 134:223-7; PMID:7916721; http://dx.doi.org/10.1016/0378-1119(93) 90097-M
28. 121/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors. Neoplasia 2005; 7:486-96; PMID:15967101; http://dx.doi.org/10.1593/neo.04631
29. Siegall CB, Liggitt D, Chace D, Mixan B, Sugai J, Davidson T, Steinitz M. Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal antiinflammatory drugs. Clin Cancer Res 1997; 3:339-45; PMID:9815690
30. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001; 345:241-7; PMID:11474661; http://dx.doi.org/10.1056/NEJM200107263450402
31. Guo C, Li Z, Shi Y, Xu M, Wise JG, Trommer WE, Yuan J. Intein-mediated fusion expression, high efficient refolding, and one-step purification of gelonin toxin. Protein Expr Purif 2004; 37:361-7; PMID:15358358; http://dx.doi.org/10.1016/j.pep.2004.06.037
32. Endo Y, Mitsui K, Motizuki M, Tsurugi K. The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins. J Biol Chem 1987; 262:5908-12; PMID:3571242
33. Kreitman RJ. Immunotoxins for targeted cancer therapy. AAPS J 2006; 8:E532-51; PMID:17025272; http://dx.doi.org/10.1208/aapsj080363
34. Hosur MV, Nair B, Satyamurthy P, Misquith S, Surolia A, Kannan KK. X-ray structure of gelonin at 1.8 Å resolution. J Mol Biol 1995; 250:368-80; PMID:7608981; http://dx.doi.org/10.1006/jmbi.1995.0383
35. Li HG, Huang PL, Zhang D, Sun Y, Chen HC, Zhang J, Huang PL, Kong XP, Lee-Huang S. A new activity of anti-HIV and anti-tumor protein GAP31: DNA adenosine glycosidase - structural and modeling insight into its functions. Biochem Biophys Res Commun 2010; 391:340-5; PMID:19913503; http://dx.doi.org/10. 1016/j.bbrc.2009.11.060
36. Li Z, Qu Y, Li H, Yuan J. Truncations of gelonin lead to a reduction in its cytotoxicity. Toxicology 2007; 231:129-36; PMID:17222956; http://dx.doi.org/10.1016/j.tox.2006.11.074
37. Daniele L, Sapino A. Anti-HER2 treatment and breast cancer: state of the art, recent patents, and new strategies. Recent Pat Anticancer Drug Discov 2009; 4:9-18; PMID:19149684; http://dx.doi.org/10.2174/157489209787002489
38. Verri E, Guglielmini P, Puntoni M, Perdelli L, Papadia A, Lorenzi P, Rubagotti A, Ragni N, Boccardo F. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. Oncology 2005; 68:154-61; PMID:16020953; http://dx.doi.org/10.1159/000086958
39. Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 2007; 357:39-51; PMID:17611206; http://dx.doi.org/10.1056/ NEJMra043186
40. Dirix LY, Rutten A, Huget P, Dirix M. Trastuzumab emtansine in breast cancer. Expert Opin Biol Ther 2013; 13:607-14; PMID:23477731; http://dx.doi.org/10.1517/14712598.2013.778238
41. Carter P, Kelley RF, Rodrigues ML, Snedecor B, Covarrubias M, Velligan MD, Wong WL, Rowland AM, Kotts CE, Carver ME, et al. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Bio/Technology 1992; 10:163-7; PMID:1368228; http://dx.doi.org/10.1038/nbt0292- 163
42. Nelson AL, Reichert JM. Development trends for therapeutic antibody fragments. Nat Biotechnol 2009; 27:331-7; PMID:19352366; http://dx.doi.org/10. 1038/nbt0409-331
43. Skerra A. A general vector, pASK84, for cloning, bacterial production, and single-step purification of antibody Fab fragments. Gene 1994; 141:79-84; PMID:8163179; http://dx.doi.org/10.1016/0378-1119(94)90131-7
44. Skerra A, Pfitzinger I, Plückthun A. The functional expression of antibody Fv fragments in Escherichia coli : improved vectors and a generally applicable purification technique. Bio/Technology 1991; 9:273-8; PMID:1367302; http://dx.doi.org/10.1038/nbt0391-273
45. Schmidt TG, Skerra A. The Strep-tag system for one-step purification and high-affinity detection or capturing of proteins. Nat Protoc 2007; 2:1528-35; PMID:17571060; http://dx.doi.org/10.1038/nprot.2007.209
46. Schlapschy M, Grimm S, Skerra A. A system for concomitant overexpression of four periplasmic folding catalysts to improve secretory protein production in Escherichia coli. Protein Eng Des Sel 2006; 19:385-90; PMID:16720693; http://dx.doi.org/10.1093/protein/gzl018
47. Sherman F, Stewart JW, Tsunasawa S. Methionine or not methionine at the beginning of a protein. BioEssays 1985; 3:27-31; PMID:3024631; http://dx.doi.org/10.1002/bies.950030108
48. Mogk A, Schmidt R, Bukau B. The N-end rule pathway for regulated proteolysis: prokaryotic and eukaryotic strategies. Trends Cell Biol 2007; 17:165-72; PMID:17306546; http://dx.doi.org/10.1016/j.tcb.2007.02.001
49. Schneider TD, Stormo GD, Gold L, Ehrenfeucht A. Information content of binding sites on nucleotide sequences. J Mol Biol 1986; 188:415-31; PMID:3525846; http://dx.doi.org/10.1016/0022-2836(86)90165-8
50. Pritz S, Wolf Y, Kraetke O, Klose J, Bienert M, Beyermann M. Synthesis of biologically active peptide nucleic acid-peptide conjugates by sortase-mediated ligation. J Org Chem 2007; 72:3909-12; PMID:17432905; http://dx.doi.org/10. 1021/jo062331l
51. Kobashigawa Y, Kumeta H, Ogura K, Inagaki F. Attachment of an NMR-invisible solubility enhancement tag using a sortase-mediated protein ligation method. J Biomol NMR 2009; 43:145-50; PMID:19140010; http://dx.doi.org/10.1007/s10858-008-9296-5
52. Huang X, Aulabaugh A, Ding W, Kapoor B, Alksne L, Tabei K, Ellestad G. Kinetic mechanism of Staphylococcus aureus sortase SrtA. Biochemistry 2003; 42:11307-15; PMID:14503881; http://dx.doi.org/10.1021/bi034391g
53. Lu C, Zhu J, Wang Y, Umeda A, Cowmeadow RB, Lai E, Moreno GN, Person MD, Zhang Z. Staphylococcus aureus sortase A exists as a dimeric protein in vitro. Biochemistry 2007; 46:9346-54; PMID:17658894; http://dx.doi.org/10.1021/ bi700519w
54. Ilangovan U, Ton-That H, Iwahara J, Schneewind O, Clubb RT. Structure of sortase, the transpeptidase that anchors proteins to the cell wall of Staphylococcus aureus. Proc Natl Acad Sci U S A 2001; 98:6056-61; PMID:11371637; http://dx.doi.org/10.1073/pnas.101064198
55. Naik MT, Suree N, Ilangovan U, Liew CK, Thieu W, Campbell DO, Clemens JJ, Jung ME, Clubb RT. Staphylococcus aureus Sortase A transpeptidase. Calcium promotes sorting signal binding by altering the mobility and structure of an active site loop. J Biol Chem 2006; 281:1817-26; PMID:16269411; http://dx.doi.org/10.1074/jbc.M506123200
56. HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89:4285-9; PMID:1350088; http://dx.doi.org/10.1073/pnas.89.10.4285
57. Gerstner RB, Carter P, Lowman HB. Sequence plasticity in the antigen-binding site of a therapeutic anti-HER2 antibody. J Mol Biol 2002; 321:851-62; PMID:12206766; http://dx.doi.org/10.1016/S0022-2836(02)00677-0
58. erbB2. Science 1992; 256:1205-10; PMID:1350381; http://dx.doi.org/10.1126/science.256.5060.1205
59. Hung MC, Zhang X, Yan DH, Zhang HZ, He GP, Zhang TQ, Shi DR. Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer. Cancer Lett 1992; 61:95-103; PMID:1346099; http://dx.doi.org/10.1016/0304-3835(92)90166-S
60. Ishiyama M, Shiga M, Sasamoto K, Mizoguchi M, He P. A new sulfonated tetrazolium salt that produces a highly water-soluble formazan dye. Chem Pharm Bull (Tokyo) 1993; 41:1118-22; http://dx.doi.org/10.1248/cpb.41.1118
61. Rangan SR. A new human cell line (FaDu) from a hypopharyngeal carcinoma. Cancer 1972; 29:117-21; PMID:4332311; http://dx.doi.org/10.1002/1097- 0142(197201)29:1〈117::AIDCNCR2820290119〉3.0.CO;2-R
62. Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973; 51:1409-16; PMID:4357757
63. Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 2004; 64:2047-53; PMID:15026342; http://dx.doi.org/10.1158/0008-5472.CAN-03-3096
64. HER2 monoclonal antibodies. Cancer Immunol Immunother 1993; 37:255-63; PMID:8102322; http://dx.doi.org/10.1007/BF01518520
65. Rosenblum MG, Shawver LK, Marks JW, Brink J, Cheung L, Langton-Webster B. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models. Clin Cancer Res 1999; 5:865-74; PMID:10213223
66. Barok M, Tanner M, Köninki K, Isola J. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res 2011; 13:R46; PMID:21510863; http://dx.doi.org/10.1186/bcr2868
67. Cao Y, Marks JW, Liu Z, Cheung LH, Hittelman WN, Rosenblum MG. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies. Oncogene 2013; PMID:23376850; http://dx.doi.org/10.1038/onc.2012.612
68. Xiao Y, Gao X, Maragh S, Telford WG, Tona A. Cell lines as candidate reference materials for quality control of ERBB2 amplification and expression assays in breast cancer. Clin Chem 2009; 55:1307-15; PMID:19443566; http://dx.doi.org/10.1373/clinchem.2008.120576
69. + breast cancer. Clin Breast Cancer 2011; 11:275-82; PMID:21729661; http://dx.doi.org/10.1016/j.clbc.2011.03.018
70. Arndt KM, Müller KM, Plückthun A. Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment. Biochemistry 1998; 37:12918-26; PMID:9737871; http://dx.doi.org/10.1021/bi9810407
71. Power BE, Doughty L, Shapira DR, Burns JE, Bayly AM, Caine JM, Liu Z, Scott AM, Hudson PJ, Kortt AA. Noncovalent scFv multimers of tumor-targeting anti-Lewis y hu3S193 humanized antibody. Protein Sci 2003; 12:734-47; PMID:12649432; http://dx.doi.org/10.1110/ps.0228503
72. Goldmacher VS, Scott CF, Lambert JM, McIntyre GD, Blättler WA, Collinson AR, Stewart JK, Chong LD, Cook S, Slayter HS, et al. Cytotoxicity of gelonin and its conjugates with antibodies is determined by the extent of their endocytosis. J Cell Physiol 1989; 141:222-34; PMID:2528553; http://dx.doi.org/ 10.1002/jcp.1041410129
73. Pirie CM, Hackel BJ, Rosenblum MG, Wittrup KD. Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties. J Biol Chem 2011; 286:4165-72; PMID:21138845; http://dx.doi.org/10.1074/jbc.M110.186973
74. Yuan X, Lin X, Manorek G, Howell SB. Challenges associated with the targeted delivery of gelonin to claudin-expressing cancer cells with the use of activatable cell penetrating peptides to enhance potency. BMC Cancer 2011; 11:61-71; PMID:21303546; http://dx.doi.org/10.1186/1471-2407-11-61
75. Bandtlow C, Schiweck W, Tai HH, Schwab ME, Skerra A. The Escherichia coli-derived Fab fragment of the IgM/κ antibody IN-1 recognizes and neutralizes myelin-associated inhibitors of neurite growth. Eur J Biochem 1996; 241:468-75; PMID:8917444; http://dx.doi.org/10.1111/j.1432-1033.1996.00468.x
76. Rosenblum MG, Horn SA, Cheung LH. A novel recombinant fusion toxin targeting HER-2/NEU-over-expressing cells and containing human tumor necrosis factor. Int J Cancer 2000; 88:267-73; PMID:11004679; http://dx.doi.org/10.1002/ 1097-0215(20001015)88:2〈267::AID-IJC19〉3.0.CO;2-G
77. Jones PL, Brown BA, Sands H. Uptake and metabolism of 111In-labeled monoclonal antibody B6.2 by the rat liver. Cancer Res 1990; 50(Suppl):852s-6s; PMID:2297733
78. Plückthun A, Skerra A. Expression of functional antibody Fv and Fab fragments in Escherichia coli. Methods Enzymol 1989; 178:497-515; PMID:2689841; http://dx.doi.org/10.1016/0076-6879(89)78036-8
79. Skerra A. Bacterial expression of immunoglobulin fragments. Curr Opin Immunol 1993; 5:256-62; PMID:8507403; http://dx.doi.org/10.1016/0952-7915(93) 90014-J
80. Röthlisberger D, Honegger A, Plückthun A. Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J Mol Biol 2005; 347:773-89; PMID:15769469; http://dx.doi.org/10.1016/j.jmb.2005.01.053
81. Lambert JM, Senter PD, Yau-Young A, Blättler WA, Goldmacher VS. Purified immunotoxins that are reactive with human lymphoid cells. Monoclonal antibodies conjugated to the ribosome-inactivating proteins gelonin and the pokeweed antiviral proteins. J Biol Chem 1985; 260:12035-41; PMID:4044586
82. Skerra A. Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in Escherichia coli. Gene 1994; 151:131-5; PMID:7828861; http://dx.doi.org/10.1016/0378-1119(94)90643-2
83. Schlapschy M, Theobald I, Mack H, Schottelius M, Wester HJ, Skerra A. Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life. Protein Eng Des Sel 2007; 20:273-84; PMID:17595342; http://dx.doi.org/10.1093/protein/gzm020
84. Studier FW, Moffatt BA. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J Mol Biol 1986; 189:113-30; PMID:3537305; http://dx.doi.org/10.1016/0022-2836(86)90385-2
85. Strauch KL, Beckwith J. An Escherichia coli mutation preventing degradation of abnormal periplasmic proteins. Proc Natl Acad Sci U S A 1988; 85:1576-80; PMID:3278319; http://dx.doi.org/10.1073/pnas.85.5.1576
86. Schiweck W, Skerra A. Fermenter production of an artificial Fab fragment, rationally designed for the antigen cystatin, and its optimized crystallization through constant domain shuffling. Proteins 1995; 23:561-5; PMID:8749852; http://dx.doi.org/10.1002/prot.340230411
87. Mao H, Hart SA, Schink A, Pollok BA. Sortase-mediated protein ligation: a new method for protein engineering. J Am Chem Soc 2004; 126:2670-1; PMID:14995162; http://dx.doi.org/10.1021/ja039915e
88. Fling SP, Gregerson DS. Peptide and protein molecular weight determination by electrophoresis using a high-molarity tris buffer system without urea. Anal Biochem 1986; 155:83-8; PMID:3454661; http://dx.doi.org/10. 1016/0003-2697(86)90228-9
89. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera - a visualization system for exploratory research and analysis. J Comput Chem 2004; 25:1605-12; PMID:15264254; http://dx.doi.org/10. 1002/jcc.20084